Visszavonva4. fázis
Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD
A legfontosabb adatok
- Ki végzi
- Johns Hopkins University
- Hol
- Baltimore (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Visszavonva
- Fázis
- 4. fázis
- Kezdés
- 2024. ápr. 16.
- Várható befejezés
- 2029. jan.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Methylphenidate
- Placebo
- A regiszteradat frissítve
- 2024. március 15.
- Miért állt le
- Study withdrawn in IRB by PI
Ki vehet részt
- Életkor
- 6 év – 18 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Age 6 to 18 years
- Diagnosis of ADHD
- A score of at least 3 (mildly ill) on the clinician administered Clinical Global Impressions-Severity (CGI-S)
Ki nem vehet részt
- Currently taking stimulant medications (within one week of first study visit). Patients will not be asked to discontinue any treatments for the purpose of this research study. Subjects will include treatment naïve patients and patients who were previously treated with stimulant medications, but are not currently treated, and meet study criteria
- Having an adverse reaction to methylphenidate, or other stimulant medication
- Having a contraindication to MRI, including a pacemaker, defibrillator or other medical implant, other metal objects, or claustrophobia, or for having braces or other metal in the head region (likely to create an artifact on the MRI scans)
- Current psychiatric disorder, including bipolar I or II disorder, major depressive, disorder, obsessive-compulsive disorder, autism spectrum disorder, Tourette syndrome, or history of psychosis
- Confirmed genetic disorder with cognitive and/or behavioral disturbances
- Active, unstable medical illness that may interfere with cognition or compromises safety of the patient
- History of head trauma with loss of consciousness or any evidence of functional impairment due to, and persisting after, head trauma
- Neurological disorder, mental retardation, intellectual or disability, or other non-ADHD cause of cognitive impairment
- Patient is at risk for clinically significant deterioration due to study protocol, as assessed by primary medical investigator (Dr. Grant)
- Pregnant or breast-feeding women
- Currently smoking or using controlled or illicit substances, including alcohol
Helyszínek itt: Egyesült Államok
- Johns Hopkins School of MedicineBaltimore, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this proposal is to develop brain imaging tools to measure the effects of methylphenidate in children and adolescents with attention deficit hyperactivity disorder (ADHD). Methylphenidate is an FDA-approved treatment for ADHD. Specifically, the investigators will correlate brain activity during cognitive tasks and brain chemistry with cognitive performance. These measures could help the investigators understand how current ADHD medications work and then could be used to develop novel drugs to treat ADHD in children and adolescents.
A vizsgálat 3 csoportja
- Methylphenidate - low doseA vizsgált kezelés
5 mg of methylphenidate
Kezelés: Methylphenidate
- Methylphenidate - high doseA vizsgált kezelés
10 mg of methylphenidate
Kezelés: Methylphenidate
- PlaceboPlacebo, összehasonlításként
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Children and Adolescents With ADHD
- A regiszteradat frissítve
- 2024. március 15.